Delving into the Latest Updates on Perception Neuroscience Holdings, Inc. with Synapse

Overview

Tags

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Top 5 Drug Type	Count

Small molecule drug	1

This is a double-blind, randomized, placebo-controlled, multicenter study comprised of 3 phases:screening (up to 2 weeks [Day -15 to Day -2]), In-Clinic Treatment (Day -1 to Day 2; including double-blind treatment [Day 1]), and post-treatment follow-up (7 and 14 days after infusion on Days 8 and 15, respectively). A total of 93 adult subjects with TRD will be randomly allocated in equal cohorts of 31 subjects/arm to the 3 arms of the study in a blinded manner.

Start Date01 Feb 2022

Sponsor / Collaborator

Perception Neuroscience Holdings, Inc.

[+2]

100 Clinical Results associated with Perception Neuroscience Holdings, Inc.

Login to view more data

0 Patents (Medical) associated with Perception Neuroscience Holdings, Inc.

Login to view more data

100 Deals associated with Perception Neuroscience Holdings, Inc.

Login to view more data

100 Translational Medicine associated with Perception Neuroscience Holdings, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data